An Endogenous Ligand for Type II Binding Sites in Normal and Neoplastic Tissues
The rat uterus contains two classes of specific nuclear estrogen binding sites which may be involved in estrogen action. Type I sites represent the classic estrogen receptor (Kd 1 nM) and type II sites (Kd 10–20 nM) are stimulated in the nucleus by estrogen under conditions which cause uterine hyperplasia. Dilution of uterine nuclear fractions from estrogen treated rats prior to quantitation of estrogen binding sites by [3H]-estradiol exchange results in an increase (3–4 fold) in the measurable quantities of the type II site. Estimates of type I sites are not affected by dilution. These increases in type II sites following nuclear dilution occur independently of protein concentration and result from the dilution of a specific endogenous inhibitor of [3H]-estradiol binding to these sites. The inhibitor activity is present in cytosol preparations from rat uterus, spleen, diaphragm, skeletal muscle and serum. Preliminary characterization of the inhibitor activity by Sephadex G-25 chromatography shows two distinct peaks which are similar in molecular weight (300). These components (α and β) can be separated on LH-20 chromatography since the β-peak component is preferentially retained on this lipophilic resin. Partial purification of the LH-20-β inhibitor component by high performance liquid chromatography and gas-liquid chromatographymass spectrometric analysis suggest the putative inhibitor activity is not steroidal in nature and consists of two very similar phenanthrene-like molecules (molecular weights 302 and 304). Analysis of cytosol preparations on LH-20 chromatography shows that non-neoplastic tissues (uterus, liver, lactating mammary gland) contain both α and β inhibitor components whereas estrogen-induced rat mammary tumors contain very low to non-measurable quantities of the β-peak inhibitor activity.
KeywordsInhibitor Component Nuclear Type Putative Inhibitor Cytosol Preparation Estradiol Binding
Unable to display preview. Download preview PDF.
- 1.E. V. Jensen, M. Numata, P. I. Brecher, and E. R. DeSombre, in The Biochemsitry of Steroid Hormone Action (Smellie, R.M.S., ed.) pp 133–159, Academic Press, Longon (1971).Google Scholar
- 2.G. Shyamala and J. Gorski, J. Biol. Chem. 244: 1097 (1967).Google Scholar
- 7.B. M. Markaverich, M. Williams, S. Upchurch, and J. H. Clark, Endocrinology 62–69 (1981).Google Scholar
- 8.J. H. Clark and B. M. Markaverich, in The Nuclear Envelope and the Nuclear Matrix, pp 260–269, Alan R. Liss, Inc., New York (1982).Google Scholar
- 10.K. L. Keiner and E. J. Peck, Jr., J. Receptor Res. 2: 47 (1981).Google Scholar
- 11.C. S. Watson and J. H. Clark, J. Receptor Res. 1: 91 (1980).Google Scholar
- 15.B. M. Markaverich, R. R. Roberts, M. A. Alejandro, and J. H. Clark, Cancer Res. 44: 1575 (1984).Google Scholar